US pharmaceutical company E. Lilly filed a complaint against Iceland’s Actavis last week to prevent it from selling a copy of its drug Strattera, which is used against hyperactivity, until its patent expires in May 2017.
Actavis has submitted a request for selling the drug to the US Food and Drug Administration, but last Wednesday E. Lilly filed a complaint to the Administration, demanding Actavis would not be given permission to do so until E. Lilly’s patent expires, Bladid reports.
E. Lilly profited more than USD 280 million (EUR 205 million) during the first half of this year by selling Strattera.
Click here to read more about Actavis.
